The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
ECDC’s annual surveillance reports provide a wealth of epidemiological data to support decision-making at the national level. They are mainly intended for public health professionals and policymakers involved in disease prevention and control programmes.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
In 2021, 1 567 cases of mumps were reported to ECDC by 27 European Union/European Economic Area(EU/EEA) Member States, with an overall notification rate of 0.4 cases per 100 000 population. This wassignificantly lower than the notification rates reported during the previous four years (range 1.7-4.2).